Comparison table: DPP-4 inhibitors (Gliptins)

Comparison table documents are designed to support prescribers and medicines management teams to maximise health gains through the optimum use of medicines within a specific therapeutic area.

There are currently five dipeptidyl peptidase-4 (DPP-4) inhibitors (or gliptins) available in the UK for the management of type 2 diabetes mellitus. There are a number of differences between the DPP-4 inhibitors in terms of licensing, interactions, renal impairment dose adjustment, hepatic impairment dose adjustment, and cost. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.

Formulary assessment tool: Glucagon (Ogluo)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The Formulary assessment tool for Glucagon (Ogluo) can be found here.

Formulary assessment tool: metolazone (Xaqua)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The Formulary assessment for metolazone (Xaqua) can be found here.

Medicines in Practice: Optimising the use of morphine 10mg/5mL oral solution in primary care (Update)

Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.

Opioids are effective for acute pain and pain at the end of life, but there is little evidence of their effectiveness for long term pain. This document supports primary care teams to review patients receiving regular large quantities of morphine 10mg/5mL oral solution and includes advice on how these patients could be managed.

This update includes:

  • opioid equivalence information to align with the updated Opioids Aware information
  • information on safety issues identified with morphine oral solution 10mg/5mL.
  • details regarding the NHSBSA Epact2 opioid dashboard which can be used to identify patients for review.

Formulary assessment tool: melatonin (Adaflex) for ADHD

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The Formulary assessment for melatonin (Adaflex) for ADHD can be found here.

Medicines in Practice: Budesonide orodispersible tablets for maintenance of remission in eosinophilic oesophagitis

Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.

Budesonide orodispersible tablets (Jorveza) are indicated for induction and maintenance of remission in adults with eosinophilic oesophagitis. A NICE technology appraisal recommended budesonide ODT for induction of remission but did not address maintenance. This review assesses the evidence for use in maintenance treatment.

Strategic Insight: Electronic repeat dispensing: Understanding the prescribing population & initial barriers to uptake

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders.

This report highlights the benefits of electronic repeat dispensing (eRD) and examines its use at ICS level in the North of England, in order to support systems in identifying where prescribing processes may be further streamlined.

Formulary assessment tool: tirbanibulin (Klisyri)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The formulary assessment tool for tirbanibulin (Klisyri) can be found here.

New Drug Evaluation: Estradiol / progesterone (Bijuve®) for hormone replacement therapy in postmenopausal women

New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.

The new drug evaluation for estradiol / progesterone (Bijuve®) can be found here.

Formulary assessment tool: testosterone 2% gel (Tostran) in post-menopausal women

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The Formulary assessment tool for testosterone 2% gel (Tostran) in post-menopausal women can be found here.